Divi's Laboratories Ltd.

NSE: DIVISLAB | BSE: 532488 | ISIN: INE361B01024 | Industry: Pharmaceuticals
| Expensive Performer
6248.5000 97.00 (1.58%)
NSE Aug 25, 2025 15:31 PM
Volume: 439.7K
 

6248.50
1.58%
Motilal Oswal
DIVIs reported strong revenue growth of ~29% YoY to INR13.4b v/s our est. of INR12.2b, partly due to low base of last year. Gross margin expanded ~360bp YoY (+110bp QoQ) to 64.2%. EBITDA margin improved significantly by ~600bp YoY to 39% due to improvement in gross margin and better operating leverage. Employee cost 2 February 2019 increased at a lower rate of 19% YoY to INR1.4b, and other expenses remained stable at INR1.6b. Revenue growth coupled with margin expansion led to ~53% YoY growth in EBITDA to INR5.2b v/s our est.
Prabhudas Lilladhar decreased Accumulate price target of Divi's Laboratories Ltd. to 6550.0 on 07 Aug, 2025.
More from Divi's Laboratori…
All earning calls
Investor presentations from Divi's Laboratori…
All investor presentations